SecBot SecBot
Biotech Drug Report Generated Nov 11, 2026

SPRAVATO

JNJ·JOHNSON & JOHNSON
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed since 2019 (adjunctive TRD) and expanded to monotherapy in January 2025.
Why 4/10
Spravato is already FDA-approved and commercially marketed with no pending regulatory decision or pivotal readout in the next ~12 months. The next hard, dated catalyst is not a binary regulatory event but continued commercial execution; therefore the impact score is capped at 4.
Actionable Insight NEUTRAL

Spravato is a steady growth contributor within JNJ's broader Innovative Medicine segment, not a binary catalyst for the stock. Watch for quarterly sales trends as a read on commercial adoption, and monitor the COMP360 psilocybin NDA (submitted November 2026) as potential future competition in the treatment-resistant depression space.

Price Chart

Loading chart...

Executive Summary

Spravato (esketamine) is Johnson & Johnson's FDA-approved nasal spray for treatment-resistant depression (TRD). Originally approved in 2019 as an add-on therapy with an oral antidepressant, it received a major label expansion in January 2025 as the first and only monotherapy for TRD. The drug is a Schedule III controlled substance administered in a healthcare setting under a REMS program due to sedation and dissociation risks. Spravato has shown consistent quarter-over-quarter sales growth and is considered a growth driver in JNJ's neuroscience portfolio. In September 2026, JNJ's Janssen subsidiary won a patent infringement case against Sandoz, protecting the drug from generic competition. However, competition is emerging: Compass Pathways submitted an NDA for COMP360 psilocybin for TRD in November 2026, which could become the first FDA-approved classic psychedelic. For JNJ, a $100B+ revenue company, Spravato is a meaningful but not dominant product.

How It Works

Spravato (esketamine) is a nasal spray form of a ketamine-like drug. It works differently from standard antidepressants by blocking a brain receptor called NMDA, which rapidly increases levels of glutamate, a chemical that helps brain cells communicate. This can quickly improve mood in people with depression that has not responded to other treatments.

Trial Status

Spravato is FDA-approved and commercially available. Real-world evidence studies (ECHO cohort, 570 patients across Europe and Israel) have shown robust effectiveness and durable effect in treatment-resistant depression. The VA began administering Spravato to eligible veterans.

The Two-Sided Case

▲ Bull Case5
Spravato has shown consistent quarter-over-quarter sales growth, with Jefferies analysts citing its momentum as supporting the commercial viability of psychedelic-based mental health treatments.
The January 2025 FDA approval as a monotherapy (the first and only for TRD) significantly expanded the addressable patient population beyond the original adjunctive-only label.
JNJ won a patent infringement case against Sandoz in September 2026, protecting Spravato from generic competition and extending its market exclusivity.
Real-world data from the ECHO study (570 patients across Europe and Israel) confirmed robust effectiveness and durable effect in a severe, chronic TRD population.
The VA began administering Spravato to eligible veterans, indicating institutional adoption and reimbursement support.
▼ Bear Case5
Spravato requires administration in a certified healthcare setting under a REMS program, with monitoring for sedation and dissociation, which limits patient access and convenience (up to ~50 visits per year per the VA).
Compass Pathways submitted an NDA for COMP360 psilocybin for TRD in November 2026, which could become the first FDA-approved classic psychedelic and compete for the same patient population.
As a Schedule III controlled substance, Spravato faces regulatory and prescribing barriers that oral, non-controlled antidepressants do not.
Spravato is a small part of JNJ's overall business (JNJ expects ~$101B in 2026 revenue), so even strong Spravato growth has limited impact on the stock.
The broader ketamine/psychedelic treatment space is becoming more crowded, with multiple companies developing competing ketamine-based and psychedelic therapies.

Upcoming Catalysts

  • Continued quarterly sales growth trajectory as a read on commercial adoption of the monotherapy label.
  • Compass Pathways' COMP360 psilocybin NDA review timeline (submitted Nov 2026) as a potential competitive threat.
  • Any further label expansion or new indication studies for esketamine.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

JOHNSON & JOHNSON 8-K JNJ ·Originating report

Sources · 6

Hover a chip for the title
1 labroots.com2 nasdaq.com3 military.com4 nytimes.com5 ajmc.com6 proactiveinvestors.co.uk